Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zanubrutinib

FDA-approved product (capsule, oral), marketed as Brukinsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Zanubrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zanubrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zanubrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

    NCT07674810 · start 2026-12-31

    Registered record
    Registry ID
    NCT07674810
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Zanubrutinib; Obinutuzumab; Sonrotoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2029-04-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionZanubrutinib; Obinutuzumab; Sonrotoclax
    PhasePhase 2
    Registry statusNot yet recruiting

  • Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    NCT07734038 · start 2026-10-01

    Registered record
    Registry ID
    NCT07734038
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Magnetic Resonance Imaging; Venetoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2027-12-31
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma

    NCT07799220 · start 2026-09

    Registered record
    Registry ID
    NCT07799220
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Zanubrutinib; Obinutuzumab; Sonrotoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-09
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionZanubrutinib; Obinutuzumab; Sonrotoclax
    PhasePhase 2
    Registry statusNot yet recruiting

  • AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL

    NCT07717177 · start 2026-06-30

    Registered record
    Registry ID
    NCT07717177
    Conditions
    Large B-Cell Lymphoma (LBCL)
    Interventions
    Polatuzumab Vedotin; Rituximab (R); Zanubrutinib; Lenalidomide; Glofitamab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06-30
    Completion
    2029-12-31
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLarge B-Cell Lymphoma (LBCL)
    InterventionPolatuzumab Vedotin; Rituximab (R); Zanubrutinib; Lenalidomide +1 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

    NCT07671378 · start 2026-06-01

    Registered record
    Registry ID
    NCT07671378
    Conditions
    CLL (Chronic Lymphocytic Leukemia)
    Interventions
    Zanubrutinib and sonrotoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2030-12-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCLL (Chronic Lymphocytic Leukemia)
    InterventionZanubrutinib and sonrotoclax
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

    NCT07418190 · start 2026-02-01

    Registered record
    Registry ID
    NCT07418190
    Conditions
    Relapsed/Refractory Follicular Lymphoma
    Interventions
    tislelizumab + zanubrutinib + rituximab + lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2029-12-31
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Follicular Lymphoma
    Interventiontislelizumab + zanubrutinib + rituximab + lenalidomide
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

    NCT07277231 · start 2026-01-22

    Registered record
    Registry ID
    NCT07277231
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Sonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-22
    Completion
    2031-11
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionSonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
    PhasePhase 3
    Registry statusRecruiting

  • Mosunetuzumab for CLL MRD Clearance

    NCT07052695 · start 2025-11-24

    Registered record
    Registry ID
    NCT07052695
    Conditions
    Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    Interventions
    Mosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-11-24
    Completion
    2032-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    InterventionMosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

    NCT07371923 · start 2025-11-20

    Registered record
    Registry ID
    NCT07371923
    Conditions
    Diffuse Large B Cell Lymphoma (DLBCL)
    Interventions
    Zanubrutinib+Pola-R-CHP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-20
    Completion
    2028-08-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma (DLBCL)
    InterventionZanubrutinib+Pola-R-CHP
    PhasePhase 2
    Registry statusRecruiting

  • SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

    NCT07021495 · start 2025-07-29

    Registered record
    Registry ID
    NCT07021495
    Conditions
    Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2029-12-31
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

    NCT06167785 · start 2025-06-04

    Registered record
    Registry ID
    NCT06167785
    Conditions
    Large B-cell Lymphoma
    Interventions
    Tislelizumab; Zanubrutinib; Tislelizumab + Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-04
    Completion
    2029-12
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLarge B-cell Lymphoma
    InterventionTislelizumab; Zanubrutinib; Tislelizumab + Zanubrutinib
    PhasePhase 2
    Registry statusRecruiting

  • Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

    NCT06849713 · start 2025-05-16

    Registered record
    Registry ID
    NCT06849713
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL)
    Interventions
    Zanubrutinib; Sonrotoclax; Obinutuzumab; Tacabrutideg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-16
    Completion
    2030-03-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL)
    InterventionZanubrutinib; Sonrotoclax; Obinutuzumab; Tacabrutideg
    PhasePhase 2
    Registry statusRecruiting

  • Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

    NCT06918015 · start 2025-05-01

    Registered record
    Registry ID
    NCT06918015
    Conditions
    BTK Inhibitors; Follicular Lymphoma; Immunochemotherapy
    Interventions
    ZGCVP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2030-05-01
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBTK Inhibitors; Follicular Lymphoma; Immunochemotherapy
    InterventionZGCVP
    PhasePhase 2
    Registry statusNot yet recruiting

  • BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

    NCT06854003 · start 2025-04-22

    Registered record
    Registry ID
    NCT06854003
    Conditions
    Mantle Cell Lymphoma; Lymphoma
    Interventions
    Bendamustine; Rituximab; Cytarabine; Zanubrutinib; Sonrotoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-22
    Completion
    2039-11-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma; Lymphoma
    InterventionBendamustine; Rituximab; Cytarabine; Zanubrutinib +1 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

    NCT06697184 · start 2025-01-23

    Registered record
    Registry ID
    NCT06697184
    Conditions
    Chronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma; MCL
    Interventions
    Sonrotoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-01-23
    Completion
    2032-11-30
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma; MCL
    InterventionSonrotoclax; Zanubrutinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting